PHOTO
- Glaucoma is a neurodegenerative eye disease and one of the most common causes of blindness worldwide[2]
- 40,000 patients out of a pool of 250,000 are getting the right treatment in the UAE. This reflects the continued need to drive awareness across the country[3]
The United Arab Emirates, Dubai: Allergan, one of the world’s leading pharmaceuticals companies announced today the launch of a new surgical treatment for refractory glaucoma in the United Arab Emirates.
The XEN Gel Implant is intended to reduce intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed.[4]
Dr. Abdulla Naqi, consultant ophthalmologist, Dubai Hospital said, “For most people, glaucoma has no symptoms or early warning signs. Vision loss may not be noticeable at first because it starts gradually at the outer edges of the field of view. It may take years for noticeable sight loss to occur. Because the symptoms of open-angle glaucoma are so subtle, it’s important to have regular eye exams.[6] Screening for glaucoma usually starts with a simple, painless test to measure the eye pressure. Patients are examined to evaluate the fluid drainage from the eye, and the optic nerve to identify any signs of damage. Additional tests of the vision and imaging tests of the optic nerve are also helpful to detect the disease.”
“In the UAE, glaucoma is the leading cause of blindness, often going unnoticed until it causes loss of vision.[7] Across the country, more awareness is needed to drive early detection and proper treatment to ultimately help reduce the pressure inside the eye. This is because diagnosing glaucoma at an early stage is essential. We encourage people to go for eye check-ups as frequently and easily as they do for blood pressure and general health checks. Testing for glaucoma is both quick and painless. This new innovative technique and launch in the UAE marks a milestone in the treatment of glaucoma patients with the latest technology. The UAE is the leading country to adopt this innovation in the Middle East, which further helps us to deliver on the National Agenda and the vision 2021, to establish a world class healthcare infrastructure.” added Dr. Abdulla Naqi.
Djamshid Ghavami, Allergan’s Gulf General Manger also noted, “Allergan has a deep, long-term commitment to developing treatments for patients with glaucoma, a sight-threatening disease that affects millions worldwide. With the launch of this innovative treatment system, patients in the UAE and the region will have access to a new treatment option for patients struggling to bring down their intraocular pressure.”
“For over 70 years, Allergan has been a leader in the eye care sector, delivering some of the most innovative products and treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our aim is to continue driving our medication innovation in the UAE and wider region with the underlying objective of creating sustainable solutions for patients,” added Ghavami.
Glaucoma is a group of eye conditions that damage the optic nerve, the health of which is vital for good vision. This damage is often caused by an abnormally high pressure in the eye. It is one of the leading causes of blindness for people over the age of 60.[8] In the UAE, 40,000 patients out of a pool of 250,000 are receiving the right treatment. This reflects the continued need to drive awareness across the country.[9]
-Ends-
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com .
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
[3] Assumptions are based on KOLs interviews, further understanding is needed to come up with more solid numbers
[4] Directions for use for the XEN*45 Glaucoma Treatment System
[5] https://www.glaucoma.org.au/articles/minimally-invasive-glaucoma-surgery-article/
[6] https://www.xengelstent.com/glaucoma
[8] https://www.mayoclinic.org/diseases-conditions/glaucoma/symptoms-causes/syc-20372839
[9] Assumptions are based on KOLs interviews, further understanding is needed to come up with more solid numbers
© Press Release 2019
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
